These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30078790)

  • 21. [Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation by mycophenolate mofetil in a murine model].
    Huang H; Zheng W; Lin M; Fu J; Zhang R
    Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):191-3. PubMed ID: 12133455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice.
    Nervi B; Rettig MP; Ritchey JK; Wang HL; Bauer G; Walker J; Bonyhadi ML; Berenson RJ; Prior JL; Piwnica-Worms D; Nolta JA; DiPersio JF
    Exp Hematol; 2007 Dec; 35(12):1823-38. PubMed ID: 17764813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation.
    Solomon SR; Nakamura R; Read EJ; Leitman SF; Carter C; Childs R; Dunbar CE; Young NS; Barrett AJ
    Bone Marrow Transplant; 2003 May; 31(9):783-8. PubMed ID: 12732885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
    Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H
    Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
    Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
    Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low Radiation Dose and Low Cell Dose Increase the Risk of Graft Rejection in a Canine Hematopoietic Stem Cell Transplantation Model.
    Lange S; Steder A; Glass Ä; Killian D; Wittmann S; Machka C; Werner J; Schäfer S; Roolf C; Junghanss C
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):637-643. PubMed ID: 26802322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cyclosporine A and mycophenolate mofetile as prophylactics for GVHD in a murine model of H-2 haploidentical nonmyeloablative bone marrow transplantation].
    Li X; Zhang Y; Sun WJ; Hou CM; Zhang MW; Wu Y; Mao N; Ai HS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Aug; 11(4):420-3. PubMed ID: 12962575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NOD Scid Gamma Mice Are Permissive to Allogeneic HSC Transplantation without Prior Conditioning.
    Verbiest T; Finnon R; Brown N; Finnon P; Bouffler S; Badie C
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827995
    [No Abstract]   [Full Text] [Related]  

  • 30. Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases.
    Nasu R; Nannya Y; Shinohara A; Ichikawa M; Kurokawa M
    Ann Hematol; 2014 Jul; 93(7):1215-23. PubMed ID: 24590535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
    Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
    Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine.
    Bleyzac N
    Fundam Clin Pharmacol; 2008 Dec; 22(6):605-8. PubMed ID: 19049662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry
    Burger DR; Parker Y; Guinta K; Lindner D
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):260-266. PubMed ID: 29128556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease.
    Bruck F; Belle L; Lechanteur C; de Leval L; Hannon M; Dubois S; Castermans E; Humblet-Baron S; Rahmouni S; Beguin Y; Briquet A; Baron F
    Cytotherapy; 2013 Mar; 15(3):267-79. PubMed ID: 23265769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
    Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM
    Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood.
    Gorin NC; Piantadosi S; Stull M; Bonte H; Wingard JR; Civin C
    J Hematother Stem Cell Res; 2002 Apr; 11(2):277-92. PubMed ID: 11983099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do the immunosuppressive drugs used as treatment for graft-versus-host disease directly inhibit lymphoid tumor cell growth?
    D'Costa S; Slobod KS; Hurwitz JL
    Leuk Lymphoma; 2003 Jan; 44(1):139-42. PubMed ID: 12691154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation].
    Liu QF; Sun J; Zhang Y; Xu D; Liu XL; Xu B; Meng FY; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1143-5. PubMed ID: 14625172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic efficacy of hematopoietic stem cell transplantation in patients with chronic myelogenous leukemia].
    Liu QF; Fan ZP; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Nov; 24(11):1227-9, 1241. PubMed ID: 15567763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.